Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2024; 16(8): 2374-2381
Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2374
Consideration on immunotherapy of liver metastases of malignant tumors
Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li
Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li, Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Jia-Xin Li, Department of General Surgery, Dafang County People's Hospital, Bijie 551600, Guizhou Province, China
Author contributions: Jiang C, Zhang ZH, and Li JX contributed to this paper; Jiang C designed the overall concept and outline of the manuscript; Zhang ZH and Li JX contributed to the discussion and design of the manuscript; Jiang C and Li JX contributed to the writing and editing of the manuscript, and review of the literature.
Supported by the Project of Guizhou Provincial Department of Science and Technology, No. Qian Ke He Cheng Guo LC[2024]109.
Conflict-of-interest statement: All the authors declare no conflict of interest related to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia-Xin Li, MD, Assistant Professor, Chief Doctor, Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu 610041, Sichuan Province, China. lijiaxin@scu.edu.cn
Received: March 10, 2024
Revised: May 5, 2024
Accepted: June 3, 2024
Published online: August 27, 2024
Processing time: 159 Days and 1.7 Hours
Core Tip

Core Tip: Immunotherapy is an important treatment method for solid tumors nowadays. However, liver metastasis leads to a decrease in the efficacy of immunotherapy for malignant tumors. The main reason is that liver metastasis can promote the depletion of systemic CD8(+) T cells by utilizing the host's peripheral immune tolerance mechanism, thereby leading to a systemic immune tolerance environment. In the dilemma of limited efficacy of immunotherapy alone, the combination with chemotherapy, radiotherapy, targeted therapy, and other anti-tumor methods can significantly enhance the efficacy of immunotherapy, holding important clinical prospects.